Rhofade approval expected early 2017

allergan

One little pearl from the Allergan investor presentation is that the company is expecting Rhofade to be approved by the FDA in early 2017.

Allergan Plc (AGN) Brenton L. Saunders on Q2 2016 Results – Earnings Call Transcript

About: Allergan plc (AGN)

William J. Meury – Chief Commercial Officer

Finally, early commercialization activities are underway to support our 2017 launches, XEN, True Tear, formerly known as Oculeve, and oxymetazoline for rosacea, which we’re now calling Rhofade.

Following FDA acceptance of our NDA for oxymetazoline, Rhofade, for the topical treatment of rosacea in adults, we anticipate approval early next year.

Related Articles

About the Author

About the Author:

David Pascoe started the Rosacea Support Group in October 1998.

.

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

1 Reader Comment

  1. Rob says:

    So does approval mean product distribution or will it be another 4-6 months for product to come to market after “approval”? After years of tweaking meds and procedures I finally have my rudolph nose free of P&P’s, itching, burning, peeling, my problem is the lingering redness, I am thinking lasers again but that is not a definite for my case. I think the years of blood constantly rushing to my nose has taken a toll and lasers are just because I have no other options that I am willing to try, Mirvaso is a disaster from what I have read so that’s out. I hope the no rebound statement is in fact true. I am just afraid it will still be another year before I can get my hands on it and I think like everything else it’s gonna cost big $$$. So I hope it comes out in January and is $25.00. I am not holding my breath and hate to be a Debbie downer but have been conditioned to be this way. Good luck to everyone.

Leave a Comment

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.

%d bloggers like this: